. Author manuscript; available in PMC: 2015 May 11.

Published in final edited form as: Biol Blood Marrow Transplant. 2014 Oct 15;21(2):202–224. doi: 10.1016/j.bbmt.2014.10.003

Table 3.

Cord Blood Priming on Expansion Trials

Strategy	Trial Phase, Number of Cord Blood Units	Expected Completion
Ex vivo expansion with mesenchymal cells plus cytokines [59]	Phase III, multicenter, randomized, double unit	>24 mo
Ex vivo priming with dimethyl-PGE2 [60]	Phase II, multicenter, randomized, double unit	>24 mo
Ex vivo expansion with notch ligand, freshly cultured or off-the-shelf products [61]	Phase II, multicenter, randomized, double unit	>24 mo
Recipient treatment with dipeptidylpeptidase (DPP)-4 inhibitor [62]	Phase II, multicenter, single	>24 mo
Ex vivo priming by fucosylation [63]	Phase II, multicenter, double unit	6–12 mo
Ex vivo expansion with nicotinamide inhibitor, retains T cells [64]	Phase II, single-center, single unit	6–12 mo
Cotransplantation of CD34⁺ cells from HLA haplo-mismatched donor, myeloablative regimen [65]	Phase II, single-center, double unit	6–12 mo
Cotransplant of CD34⁺ cells from HLA haplo-mismatched donor, RIC [66]	Phase II, single-center, single unit	6–12 mo